Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:6.4.1.2 (acetyl-CoA carboxylase)
 2,876 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Intraventricular resistin is known to reduce food intake, modify hypothalamic gene expression (e.g. NPY, POMC) and influence the activity of novel metabolic enzymes (e.g. 5'AMP-activated protein kinase; AMPK) in the rodent brain. Previously we demonstrated that the hypothalamus, and the N-1 hypothalamic neuronal cell line, also expressed several adipokines, including resistin and adiponectin (ADPN). These data suggested that they might also impact brain function and metabolism. We used the N-1 hypothalamic neuronal cell line to examine NPY, AgRP, POMC, and ADPN expression following acute resistin treatment (45 min; 100 ng/mL and 1000 ng/mL). The total and phosphorylated levels of AMPKalpha and acetyl-CoA carboxylase (ACC) were subsequently assessed using Western blot analysis. Parallel investigations were also conducted following a) resistin overexpression, or b) after the RNAi-mediated attenuation of resistin mRNA in N-1 neurons. Resistin overexpression lowered POMC (-35%, p<0.01), ADPN (-23%, p<0.05) and NPY (-36%, p<0.05) mRNA as evaluated using realtime RT-PCR, although AgRP remained unchanged, and significant increases in pAMPKalpha and pACC were detected (+47% and +34% respectively, p<0.001). In contrast recombinant resistin only significantly increased the level of pAMPKalpha (+31%; p<0.05), but failed to significantly modify gene expression, in N-1 neurons. Conversely the RNAi-mediated silencing of resistin expression increased AgRP (+37%, p<0.05), POMC (+66%, p<0.0001), ADPN (+87%, p<0.0001), whereas NPY was reduced (-22%, p<0.01) along with pAMPKalpha and pACC (-43% and -35% respectively, p<0.001). In summary, these in vitro data suggest that endogenous resistin might be capable of fine-tuning the expression and enzymatic activity of various hypothalamic targets previously implicated in the delicate homeostatic control of food intake. As such, resistin may be part of an autocrine/paracrine loop, which may in turn contribute to some of the reported effects of resistin on energy metabolism.
 ...
PMID:Resistin differentially modulates neuropeptide gene expression and AMP-activated protein kinase activity in N-1 hypothalamic neurons. 1964 21

Cushing's syndrome (CS) is a collection of symptoms caused by prolonged exposure to excess cortisol. Chronically elevated glucocorticoid (GC) levels contribute to hepatic steatosis. We hypothesized that histone deacetylase inhibitors (HDACi) could attenuate hepatic steatosis through glucocorticoid receptor (GR) acetylation in experimental CS. To induce CS, we administered adrenocorticotropic hormone (ACTH; 40 ng/kg/day) to Sprague-Dawley rats by subcutaneous infusion with osmotic mini-pumps. We administered the HDACi, sodium valproate (VPA; 0.71% w/v), in the drinking water. Treatment with the HDACi decreased steatosis and the expression of lipogenic genes in the livers of CS rats. The enrichment of GR at the promoters of the lipogenic genes, such as acetyl-CoA carboxylase (Acc), fatty acid synthase (Fasn), and sterol regulatory element binding protein 1c (Srebp1c), was markedly decreased by VPA. Pan-HDACi and an HDAC class I-specific inhibitor, but not an HDAC class II a-specific inhibitor, attenuated dexamethasone (DEX)-induced lipogenesis in HepG2 cells. The transcriptional activity of Fasn was decreased by pretreatment with VPA. In addition, pretreatment with VPA decreased DEX-induced binding of GR to the glucocorticoid response element (GRE). Treatment with VPA increased the acetylation of GR in ACTH-infused rats and DEX-induced HepG2 cells. Taken together, these results indicate that HDAC inhibition attenuates hepatic steatosis hrough GR acetylation in experimental CS.
 ...
PMID:Histone deacetylase inhibition attenuates hepatic steatosis in rats with experimental Cushing's syndrome. 2930 9